Methods for inducing selective apoptosis
Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
1. A method of controlling the survival of therapeutic cells in a human patient, comprising administering a multimeric ligand to a human patient to whom therapeutic cells have been administered, wherein:
the therapeutic cells have been transfected or transduced with a nucleic acid comprising (i) a promoter region, and (ii) a polynucleotide that encodes a chimeric protein comprising a multimeric ligand binding region and a caspase 9 polypeptide;
the promoter region is operatively linked to the polynucleotide;
the multimeric ligand binds to the multimeric ligand binding region;
the multimeric ligand binding region comprises a modified FKBP12 polypeptide;
the modified FKBP12 polypeptide binds with higher affinity to the multimeric ligand than the wild type FKBP12 polypeptide;
the modified FKBP12 polypeptide comprises an amino acid substation at position 36;
the number of therapeutic cells that express the caspase 9 polypeptide is reduced at least 90% within 24 hours following administration of the multimeric ligand.
2. The method of claim 1 , wherein therapeutic cells that are not undergoing cell division are killed following administration of the multimeric ligand.
3. The method of claim 1 , wherein the multimeric ligand is AP1903.
4. The method of claim 1 , wherein the multimeric ligand is AP20187.
5. The method of claim 1 , wherein the therapeutic cells are allogeneic T cells.
6. The method of claim 1 , wherein the therapeutic cells are non-allodepleted.
7. The method of claim 1 , wherein the caspase-9 polypeptide is a truncated caspase-9 polypeptide.
8. The method of claim 1 , wherein the modified FKBP12 polypeptide binds with higher affinity to AP1903 than the wild type FKBP12 polypeptide.
9. The method of claim 1 , wherein the FKBP12 polypeptide comprises a valine at position 36.
10. The method of claim 1 , further comprising administering a haploidentical stem cell transplant to the patient.
11. The method of claim 1 , wherein the chimeric protein further comprises a marker polypeptide.
12. The method of claim 1 , wherein the number of therapeutic cells is reduced at least 90% within 30 minutes following administration of the multimeric ligand.
13. The method of claim 1 , wherein the FKBP12 polypeptide is encoded by a wobbled nucleotide sequence.
14. The method of claim 1 , comprising administering a composition comprising the therapeutic cells to the patient prior to administering the multimeric ligand to the patient.
15. The method of claim 14 , wherein the therapeutic cells are allogeneic T cells.
16. The method of claim 15 , wherein the T cells are not in an active state when administered to the patient.
17. The method of claim 15 , wherein the composition comprising the T cells is over 90% pure.
18. A method of controlling the survival of therapeutic cells in a human patient, comprising administering a multimeric ligand to a human patient to whom therapeutic cells have been administered, wherein:
the therapeutic cells have been transfected or transduced with a nucleic acid comprising (i) a promoter region, and (ii) a polynucleotide that encodes a chimeric protein comprising a multimeric ligand binding region and a caspase 9 polypeptide;
the promoter region is operatively linked to the polynucleotide;
the multimeric ligand binds to the multimeric ligand binding region;
the multimeric ligand is AP20187 or AP1903;
the multimeric ligand binding region comprises a modified FKBP12 polypeptide;
the modified FKBP12 polypeptide binds with higher affinity to the multimeric ligand than the wild type FKBP12 polypeptide; and
the number of therapeutic cells that express the caspase 9 polypeptide is reduced at least 90% within 24 hours following administration of the multimeric ligand.
19. The method of claim 18 , wherein therapeutic cells that are not undergoing cell division are killed following administration of the multimeric ligand.
20. The method of claim 18 , wherein the multimeric ligand is AP1903.
21. The method of claim 18 , wherein the multimeric ligand is AP20187.
22. The method of claim 18 , wherein the therapeutic cells are allogeneic T cells.
23. The method of claim 18 , wherein the therapeutic cells are non-allodepleted.
24. The method of claim 18 , wherein the caspase-9 polypeptide is a truncated caspase-9 polypeptide.
25. The method of claim 18 , wherein the modified FKBP12 polypeptide binds with higher affinity to AP1903 than the wild type FKBP12 polypeptide.
26. The method of claim 18 , wherein the FKBP12 polypeptide comprises a valine at position 36.
27. The method of claim 18 , further comprising administering a haploidentical stem cell transplant to the patient.
28. The method of claim 18 , wherein the chimeric protein further comprises a marker polypeptide.
29. The method of claim 18 , wherein the number of therapeutic cells is reduced at least 90% within 30 minutes following administration of the multimeric ligand.
30. The method of claim 18 , wherein the FKBP12 polypeptide is encoded by a wobbled nucleotide sequence.
31. The method of claim 18 , comprising administering a composition comprising the therapeutic cells to the patient prior to administering the multimeric ligand to the patient.
32. The method of claim 31 , wherein the therapeutic cells are allogeneic T cells.
33. The method of claim 32 , wherein the T cells are not in an active state when administered to the patient.
34. The method of claim 33 , wherein the composition comprising the T cells is over 90% pure.